<DOC>
	<DOC>NCT02260804</DOC>
	<brief_summary>To demonstrate that CT-P10 is similar to Rituxan in terms of efficacy as determined by overall response rate at 7 months</brief_summary>
	<brief_title>To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Confirmed diagnosis of low tumour burden, CD20+ follicular lymphoma Ann Arbor Stage II, III or IV Has receive rituximab Allergies or hypersensitivity to murine, chimeric, human or humanised proteins Previous treatment for NHL Any malignancy Current or recent treatment with any other investigational medicinal product or device pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>